BeiGene Showcases New Hematology Data at EHA2024

BeiGene, Ltd., a global oncology firm, will unveil new information from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid. The event, scheduled for June 13-16, 2024, will feature 28 abstracts from BeiGene, including four oral presentations.

Dr. Mehrdad Mobasher, Chief Medical Officer for Hematology at BeiGene, highlighted the company's ongoing commitment to expanding treatment options for B-cell malignancies. The presentations will showcase the potential of BRUKINSA® (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), and the investigational BCL2 inhibitor, sonrotoclax (BGB-11417).

Key areas of focus include:

BRUKINSA Combination with Venetoclax in CLL/SLL:
- An oral presentation will detail findings from the SEQUOIA study, which involved high-risk treatment-naïve (TN) patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) exhibiting del(17p) and/or TP53 mutations. This study showed robust efficacy and favorable safety profiles for BRUKINSA combined with venetoclax.
- Additional presentations will include an adverse event-based economic analysis comparing BRUKINSA with acalabrutinib, suggesting cost savings and quality of life benefits for BRUKINSA. Another post hoc analysis from the ALPINE trial indicated a lower frequency of new anti-hypertensive medication initiation in patients treated with BRUKINSA compared to those treated with ibrutinib.

Sonrotoclax:
- Sonrotoclax, BeiGene’s BCL2 inhibitor, will be highlighted in various studies for its promising efficacy and safety as both a monotherapy and in combination with other treatments.
- An oral presentation will cover a Phase 1 study showing significant responses in relapsed/refractory (R/R) CLL/SLL patients treated with sonrotoclax and BRUKINSA. This combination is being further evaluated in the Phase 3 CELESTIAL study.
- Poster presentations will report on sonrotoclax’s performance in R/R mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, acute myeloid leukemia, and multiple myeloma.

BGB-16673:
- The investigational BTK degrader BGB-16673, from BeiGene’s CDAC platform, will be featured in an oral presentation. This study indicates promising efficacy and tolerability in heavily pretreated patients with R/R CLL/SLL.
- Additional data will be presented on the drug’s effectiveness in various types of non-Hodgkin lymphoma, including those resistant to BTK inhibitors.

Pipeline Strengths:
- BeiGene will also present multiple additional studies emphasizing patient-reported outcomes and real-world differentiation among BTK inhibitors, underscoring the advantages of BRUKINSA across various indications.

About BRUKINSA:
BRUKINSA aims to provide continuous and thorough inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. It has shown efficacy in inhibiting the proliferation of malignant B cells in several disease-relevant tissues. It is approved for treating CLL, SLL, Waldenström’s macroglobulinemia, and other lymphomas under specific conditions.

About Sonrotoclax:
Sonrotoclax, an investigational BCL2 inhibitor, exhibits potent activity and high selectivity against the antiapoptotic protein BCL2. It shows potential in overcoming common BCL2 resistance mutations and is more selective compared to venetoclax.

About BGB-16673:
BGB-16673 is an oral BTK degrader targeting wildtype and mutant forms of BTK, developed to address resistance issues in BTK inhibitors.

BeiGene’s participation in EHA2024 underlines their strategic focus on developing and delivering innovative oncology treatments, enhancing their hematology portfolio, and maintaining a solid commitment to addressing unmet needs in blood cancer therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!